Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Oppenheimer has initiated coverage on Inova Technology, Inc. (NASDAQ:INVA) with an Outperform rating and a price target of $35.00. According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.07, with robust metrics across profitability and cash flow. The stock currently appears undervalued based on InvestingPro’s Fair Value analysis.
The research firm views Inova as a holding company with three distinct business segments: royalty distributions from Breo/Anoro, Innoviva Specialty Therapeutics (IST) commercial organization focused on acute critical care treatments, and strategic finance equity investments in both private and public companies. The company’s strong business model is reflected in its impressive 85.94% gross margin and healthy current ratio of 2.64.
Oppenheimer expects IST to reach approximately $700 million in commercial peak sales, while annual royalty revenues are projected at around $250 million.
The firm notes that commercial-focused biotech companies have been among the best performers in the sector this year, suggesting INVA’s commercial results could drive similar outperformance.
Oppenheimer also highlights potential upside to its estimates if government incentives are passed through legislature, which could boost IST sales to between $750 million and $3 billion per product.
In other recent news, Inova Technology has garnered attention with its first-quarter 2025 earnings, reporting $61 million in royalties from its COPD therapies, Breo and Anoro. These royalties are projected to continue through 2031/2033, with a net present value estimated at approximately $1 billion. Furthermore, Cantor Fitzgerald has initiated coverage on Inova Technology with an Overweight rating and a price target of $26.00. In a significant development, the U.S. Food and Drug Administration has accepted a New Drug Application for zoliflodacin, an investigational oral antibiotic developed by Innoviva Specialty Therapeutics, a subsidiary of Inova Technology, in partnership with the Global Antibiotic Research & Development Partnership. The FDA has granted Priority Review for this novel treatment intended for uncomplicated gonorrhea, with a target action date set for December 15, 2025. If approved, zoliflodacin would represent the first new treatment option for gonorrhea in many years, addressing a growing public health challenge due to drug-resistant strains.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.